We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-21.9%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
-$63.5M
Cap. Flow
+$448M
Cap. Flow %
24.92%
Top 10 Hldgs %
55.9%
Holding
105
New
11
Increased
30
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$58.4M
2
NVRO
NEVRO CORP.
NVRO
+$57.5M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$30.2M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18.2M
5
MASI
Masimo
MASI
+$17.2M

Top Sells

Rank Stock Value
1
ASRT
Assertio
ASRT
+$25.1M
2
ALR
Alere Inc
ALR
+$23.9M
3
HRTX icon
Heron Therapeutics
HRTX
+$17.8M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$12.8M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 63.28%
2 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WINT
76
DELISTED
Windtree Therapeutics Inc
WINT
$2.85M 0.16%
677,798
+119,048
+21% +$788K
CRDC
77
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$2.4M 0.13%
887,499
– –
PHIO icon
78
Phio Pharmaceuticals
PHIO
$12.1M
$2.27M 0.13%
10
– –
ALBO
79
DELISTED
Albireo Pharma Inc
ALBO
$2.27M 0.13%
171,851
-14,150
-8% -$356K
ARMP icon
80
Armata Pharmaceuticals
ARMP
$171M
$2.18M 0.12%
+3,943
New +$3.6M
CDTX
81
DELISTED
Cidara Therapeutics
CDTX
$2.12M 0.12%
8,344
+844
+11% +$241K
APYX icon
82
Apyx Medical
APYX
$165M
$1.85M 0.1%
947,400
– –
CASC
83
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.62M 0.09%
98,700
-184,633
-65% -$3.79M
AIXC
84
AIxCrypto Holdings Inc
AIXC
$16.6M
$1.59M 0.09%
6
– –
ZSAN
85
DELISTED
Zosano Pharma Corporation
ZSAN
$1.47M 0.08%
531
-162
-23% -$909K
SSKN
86
DELISTED
Strata Skin Sciences
SSKN
$1.45M 0.08%
25,486
+17,813
+232% +$1.03M
BDSI
87
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.39M 0.08%
250,000
-500,000
-67% -$3.69M
TTPH
88
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.19M 0.07%
+8,002
New +$5.87M
PTN
89
Palatin Technologies
PTN
$13.7M
$1.11M 0.06%
+1,094
New +$1.26M
ASRT
90
DELISTED
Assertio
ASRT
– –
-19,457
Closed -$25.1M
CAPR icon
91
Capricor Therapeutics
CAPR
$1.14B
– –
-11,800
Closed -$596K
COLL icon
92
Collegium Pharmaceutical
COLL
$1.14B
– –
-297,200
Closed -$5.3M
DRRX
93
DELISTED
DURECT Corp
DRRX
– –
-219,538
Closed -$5.25M
NGNE icon
94
Neurogene
NGNE
$696M
– –
-26,588
Closed -$3.69M
VSTM icon
95
Verastem
VSTM
$532M
– –
-87,500
Closed -$7.92M
XOMA
96
DELISTED
Xoma
XOMA
– –
-75,000
Closed -$5.82M
NBSE
97
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-4,438
Closed -$4.46M
ABMD
98
DELISTED
Abiomed Inc
ABMD
– –
-100,000
Closed -$6.57M
PGNX
99
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-600,000
Closed -$4.48M
ALR
100
DELISTED
Alere Inc
ALR
– –
-452,423
Closed -$23.9M
1 2 3
4
5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Broadfin Capital held 105 positions worth $1.8B, down 3.4% from $1.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Broadfin Capital deployed $448M of net new capital in Q3 2015, opening 11 new positions and adding to 30 existing holdings. Its largest new stake was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Heron Therapeutics, an estimated $17.8M trimmed.

  • Broadfin Capital's largest Q3 2015 buy was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015, an estimated $58.4M increase.
  • Broadfin Capital's biggest Q3 2015 reduction was Heron Therapeutics, cutting an estimated $17.8M.
  • Broadfin Capital fully exited Assertio in Q3 2015, selling an estimated $25.1M.
  • Broadfin Capital's ten largest holdings make up 56% of its $1.8B portfolio in Q3 2015.
  • Broadfin Capital opened 11 new positions and closed 15 in Q3 2015.
  • Broadfin Capital's portfolio value fell 3.4% quarter-over-quarter to $1.8B.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.